Glenmark Pharmaceuticals has informed regarding the closure of trading window from September 30, 2024 to November 16, 2024 for the purpose of approval of Unaudited Financial Results for the second quarter and half year ended September 30, 2024.
The above information is a part of company’s filings submitted to BSE.